FDA Panel Gives Nod To Spondyloarthritis Claim For Cimzia, But Not Humira
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee narrowly endorses approval of UCB’s TNF inhibitor but recommends the proposed indication for active disease be more limited. The same panel overwhelmingly rejects AbbVie’s bid to expand adalimumab’s use on concerns that the patient population studied was not well defined.
You may also be interested in...
Humira Shows Benefit In New Arthritis Indications Based On Novel Criteria
Abbott’s anti-TNF demonstrated an improvement in two subsets of spondyloarthritis patients using new criteria developed by the SpondyloArthritis International Society to identify and test patients.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.